Press release
Empowering Patients with Advanced Therapies: DelveInsight's Atherosclerosis Clinical Trials Report Brings Hope to Atherosclerosis Community | Bayer, Janssen, Genentech Inc, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, and others
Atherosclerosis Pipeline
In the Atherosclerosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Atherosclerosis NDA approvals (if any), and product development activities comprising the technology, Atherosclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Atherosclerosis pipeline treatment landscape of the report, click here @ Atherosclerosis Pipeline- https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Atherosclerosis Pipeline Report
• DelveInsight's Atherosclerosis Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline treatment therapies.
• The leading Atherosclerosis Companies working in the market include Bayer, Janssen, Genentech Inc, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Cardionovum GmbH, Archer Research, Sankyo Pharma GmbH, Daiichi Sankyo Inc, AstraZeneca, Omicron Pharmaceuticals, Abott, Sanofi, Pfizer, Medimmune LLC, Amgen, Hoffmann-La-Roche, Novartis, Bristol-Myers Squibb, Korea Ginseng Corporation, Solvay Pharmaceuticals, Boston Scientific Corporation, and others.
• Promising Atherosclerosis Pipeline Therapies in the various stages of development include Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid, MLDL1278A, rilapladib, Glipizide, Rosiglitazone Maleate, MK0633, Pactimibe, Olmesartan medoxomil, Rosuvastatin, Ateronon, K-604, and others.
• On May 2023, Silence Therapeutics Inc announced a study of phase 2 clinical trials for SLN360. Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein (a) at high risk of atherosclerotic cardiovascular disease events.
• On June 2023, Daiichi Sankyo Inc announced a study of phase 3 clinical trials for Olmesartan medoxomil. The purpose of this study is to determine the efficacy of treatment with olmesartan medoxomil, an Angiotensin Receptor Blocker, compared to placebo on the blood levels of surrogate markers of vascular inflammation for atherosclerotic disease. Patients will be randomized to receive either olmesartan medoxomil or placebo for one year.
• On July 2023, Novartis Pharmaceuticals announced a study of phase 3 for Inclisiran. The purpose of this study is to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with maximally tolerated statin therapy alone) compared to usual care in an ASCVD population.
• On July 2023, Amgen announced a study of phase 3 clinical trials for Olpasiran. The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein (a).
Atherosclerosis Overview
Plaque (fatty deposits) build up in arteries is called atherosclerosis. These deposits are made up of cholesterol, fatty substances, cellular waste products, calcium and fibrin (a clotting material in the blood). As plaque builds up, the wall of the blood vessel thickens.
To explore more information on the latest breakthroughs in the Atherosclerosis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Atherosclerosis Emerging Drugs Profile
• Aloricumab: Sanofi/ Regeneron
• VB 201: VBL therapeutics
Atherosclerosis Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Atherosclerosis. The Atherosclerosis companies which have their Atherosclerosis drug candidates in the most advanced stage, i.e. Registration include, Sanofi/ Regeneron.
Request a sample and discover the recent advances in Atherosclerosis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Atherosclerosis Drugs and Companies
• Rivaroxaban (BAY59-7939, Xarelto): Bayer
• Acetylsalicylic acid: Janssen LP
• MLDL1278A: Genentech Inc
• Rilapladib: GlaxoSmithKline
• MK0633: Merck Sharp & Dohme LLC
Atherosclerosis Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Atherosclerosis Therapeutics Market include-
Bayer, Janssen, Genentech Inc, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Cardionovum GmbH, Archer Research, Sankyo Pharma GmbH, Daiichi Sankyo Inc, AstraZeneca, Omicron Pharmaceuticals, Abott, Sanofi, Pfizer, Medimmune LLC, Amgen, Hoffmann-La-Roche, Novartis, Bristol-Myers Squibb, Korea Ginseng Corporation, Solvay Pharmaceuticals, Boston Scientific Corporation, and others.
Dive deep into rich insights for drugs for Atherosclerosis Pipeline, click here for Atherosclerosis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Atherosclerosis Pipeline Report
• Coverage- Global
• Atherosclerosis Companies- Bayer, Janssen, Genentech Inc, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Cardionovum GmbH, Archer Research, Sankyo Pharma GmbH, Daiichi Sankyo Inc, AstraZeneca, Omicron Pharmaceuticals, Abott, Sanofi, Pfizer, Medimmune LLC, Amgen, Hoffmann-La-Roche, Novartis, Bristol-Myers Squibb, Korea Ginseng Corporation, Solvay Pharmaceuticals, Boston Scientific Corporation, and others.
• Atherosclerosis Pipeline Therapies- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid, MLDL1278A, rilapladib, Glipizide, Rosiglitazone Maleate, MK0633, Pactimibe, Olmesartan medoxomil, Rosuvastatin, Ateronon, K-604, and others.
• Atherosclerosis Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Atherosclerosis Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Atherosclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atherosclerosis - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Atherosclerosis Collaboration Deals
9. Late Stage Products (Regsitered)
10. Aloricumab: Sanofi/ Regeneron
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. VB 201: VBL therapeutics
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. BT 200: Band Therapeutics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Atherosclerosis Key Companies
20. Atherosclerosis Key Products
21. Atherosclerosis- Unmet Needs
22. Atherosclerosis- Market Drivers and Barriers
23. Atherosclerosis- Future Perspectives and Conclusion
24. Atherosclerosis Analyst Views
25. Atherosclerosis Key Companies
26. Appendix
List of Top Selling Market Research Reports in 2023
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market
https://www.delveinsight.com/report-store/blastomycosis-market
https://www.delveinsight.com/report-store/chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-cystic-fibrosis-market
https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
https://www.delveinsight.com/report-store/digestive-system-fistula-market
https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
https://www.delveinsight.com/report-store/kawasaki-disease-market
https://www.delveinsight.com/report-store/myopia-progression-market
https://www.delveinsight.com/report-store/pecoma-market
https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
https://www.delveinsight.com/report-store/upper-tract-urothelial-cancer-market
https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
https://www.delveinsight.com/report-store/supraventricular-tachycardia-market
https://www.delveinsight.com/report-store/stem-cell-market
https://www.delveinsight.com/report-store/soft-tissue-defect-market
https://www.delveinsight.com/report-store/small-lymphocytic-lymphoma-market
https://www.delveinsight.com/report-store/shigella-infections-market
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/radiation-retinopathy-market
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Empowering Patients with Advanced Therapies: DelveInsight's Atherosclerosis Clinical Trials Report Brings Hope to Atherosclerosis Community | Bayer, Janssen, Genentech Inc, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, and others here
News-ID: 3142561 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Atherosclerosis
Leading Growth Driver in the Atherosclerosis Drugs Market in 2025: Atheroscleros …
Which drivers are expected to have the greatest impact on the over the atherosclerosis drugs market's growth?
The anticipated growth of the atherosclerosis drug market is likely due to the increased prevalence of cardiovascular diseases. These ailments usually impact the heart and blood vessels, and atherosclerosis, a condition arising from the accumulation of fats, cholesterol, and other substances on one's artery walls, is usually responsible. Key complications of atherosclerosis include coronary…
Atherosclerosis Therapeutics Market Projected to Show Strong Growth
The "Atherosclerosis Therapeutics Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. to determine market size, potential, growth trends, and competitive environment, the Atherosclerosis Therapeutics Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured…
Atherosclerosis Drugs Market Size 2024 to 2031.
Market Overview and Report Coverage
Atherosclerosis is a condition characterized by the buildup of plaque in the arteries, leading to restricted blood flow and an increased risk of heart attack or stroke. Atherosclerosis drugs are medications used to manage the symptoms and complications of this condition.
The Atherosclerosis Drugs Market is expected to grow at a CAGR of 4.00% during the forecasted period. The increasing prevalence of lifestyle-related diseases such…
Atherosclerosis Therapeutics Market: Competitive Dynamics & Global Outlook 2024
LP INFORMATION offers a latest published report on Atherosclerosis Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Atherosclerosis Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular,…
Atherosclerosis Therapeutics Market: Competitive Dynamics & Global Outlook 2025
Market Research Report Store offers a latest published report on Atherosclerosis Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
This report focuses on the key global Atherosclerosis Therapeutics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Atherosclerosis Therapeutics with respect to individual growth…
Atherosclerosis Market Revenue and Value Chain 2016-2026
Atherosclerosis is the narrowing of the vein as a result of plaque build-up. Atherosclerosis is a particular kind of arteriosclerosis (stiffening or solidifying of the artery walls). The illness disturbs the stream of blood around the body, posturing genuine cardiovascular entanglements. Atherosclerosis begins when the endothelium gets to be harmed, permitting LDL cholesterol to aggregate in the artery wall. The body sends macrophage white platelets to tidy up the cholesterol.…
